Seven biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.
Pharmacyclics, Inc. (PCYC) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
This week, Acorda Therapeutics, Inc. (ACOR) pushes up from a C to a B rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc. (NWBO) shows solid improvement this week. The company’s rating rises from a C to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
BioMarin Pharmaceutical (BMRN) earns a B this week, jumping up from last week’s grade of C. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) is seeing ratings go up from a C last week to a B this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
This week, Amgen’s (AMGN) ratings are up from a B last week to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.